1. Comment/debate › Research › Peer-reviewed
2. Published

   Challenges for economic evaluation of strategies to contain antimicrobial resistance

   Holmes, E. & Hughes, D., 27 Sept 2019, In: Antibiotics. 8, 4, 8 p., 166.

   Research output: Contribution to journal › Comment/debate › peer-review

3. Published

   Pharmacogenomics spotlight commentary: From the United Kingdom to global populations

   Magavern, E. F., Daly, A. K., Gilchrist, A. & Hughes, D., Dec 2021, In: British Journal of Clinical Pharmacology. 87, 12, p. 4546-4548 3 p., 14917.

   Research output: Contribution to journal › Comment/debate › peer-review

4. Editorial › Research › Peer-reviewed
5. Published

   Improving Medication Adherence Research Reporting: European Society for Patient Adherence, Compliance and Persistence Medication Adherence Reporting Guideline

   de Geest, S., Zullig, L., Dunbar-Jacobs, J., Hughes, D., Wilson, I. & Vrijens, B., Jun 2019, In: Journal of Cardiovascular Nursing. 34, 3, p. 199-200

   Research output: Contribution to journal › Editorial › peer-review

6. Published

   Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

   de Geest, S., Zullig, L. L., Dunbar-Jacob, J., Hughes, D., Wilson, I. & Vrijens, B., 1 Apr 2019, In: European Journal of Cardiovascular Nursing. 18, 4, p. 258-259 2 p.

   Research output: Contribution to journal › Editorial › peer-review

7. Published

   Medication adherence research comes of age

   Wright, D. F. B., Sinnappah, K. A. & Hughes, D., Jul 2023, In: British Journal of Clinical Pharmacology. 89, 7, p. 1914-1917

   Research output: Contribution to journal › Editorial › peer-review

8. Published

   Medication adherence – key considerations for clinical pharmacologists

   Hughes, D., Apr 2020, In: British Journal of Clinical Pharmacology. 86, 4, p. 628-629 2 p.

   Research output: Contribution to journal › Editorial › peer-review

9. Meeting Abstract › Research › Peer-reviewed
10. Published

    Cost effectiveness analysis of treatments for children with uncontrolled asthma symptoms despite taking inhaled corticosteroids

    Culeddu, G., Sinha, I., Donegan, S., Maden, M., Cividini, S., Rose, K., Fulton, O., Turner, S., Tudor-Smith, C. & Hughes, D., 27 Oct 2023, In: European Respiratory Journal. 62 , Supplement 67, PA 523.

    Research output: Contribution to journal › Meeting Abstract › peer-review

11. Published

    Patient preferences for outcomes in clinical trials: implications for medicines optimization

    Holmes, E., Marson, A. G. & Hughes, D., 8 May 2017, In: Trials. 18 (Suppl 1), O18, p. 192 1 p.

    Research output: Contribution to journal › Meeting Abstract › peer-review

12. Chapter › Research › Not peer-reviewed
13. Published

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 101-126

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

14. Published

    Drug evaluation and pharmocoeconomics.

    Hughes, D., Krska, J., Hughes, D. A., Winfield, A. J. (ed.), Rees, J. A. (ed.) & Smith, I. (ed.), 1 Jan 2009, Pharmaceutical Practice: 4th Edition.. 2009 ed. Churchill Livingstone, p. 185-198

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

15. Published

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (ed.) & Kermani, F. (ed.), 1 Jan 2006, Patient Compliance: Sweetening the Pill. 2006 ed. Gower Publishing, p. 23-40

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

16. Published

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 141-154

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

17. Published

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (ed.), Haycox, A. (ed.), Boland, A. (ed.) & Breckenridge, A. (ed.), 1 Jan 2004, Pharmacoeconomics. 2004 ed. Adis International, p. 167-174

    Research output: Chapter in Book/Report/Conference proceeding › Chapter

18. Chapter › Research › Peer-reviewed
19. Published

    Review of resource-use measures in UK economic evaluations

    Ridyard, C. & Hughes, D., 2015, PSSRU Unit Costs of Health and Social Care 2015 . Curtis, L. & Burns, A. (eds.). University of Kent, Canterbury, p. 22-31 10 p.

    Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

20. Paper › Research › Not peer-reviewed
21. Published

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 May 2007.

    Research output: Contribution to conference › Paper

22. Published

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Aug 2007.

    Research output: Contribution to conference › Paper

23. Published

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Nov 2004.

    Research output: Contribution to conference › Paper

24. Published

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.

    Research output: Contribution to conference › Paper

25. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.

    Research output: Contribution to conference › Paper

26. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003.

    Research output: Contribution to conference › Paper

27. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Jun 2003.

    Research output: Contribution to conference › Paper

28. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 May 2003.

    Research output: Contribution to conference › Paper

29. Published

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

30. Published

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Jun 2007.

    Research output: Contribution to conference › Paper

31. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jul 2007.

    Research output: Contribution to conference › Paper

32. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Mar 2007.

    Research output: Contribution to conference › Paper

33. Published

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Apr 2007.

    Research output: Contribution to conference › Paper

34. Published

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D. & Hughes, D. A., 1 May 2007.

    Research output: Contribution to conference › Paper

35. Published

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D., 1 Mar 2007.

    Research output: Contribution to conference › Paper

36. Published

    Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

    Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Jan 2009.

    Research output: Contribution to conference › Paper

37. Published

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

38. Published

    Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 May 2007.

    Research output: Contribution to conference › Paper

39. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

40. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

41. Published

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Sept 2006.

    Research output: Contribution to conference › Paper

42. Published

    Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

    Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Jan 2009.

    Research output: Contribution to conference › Paper

43. Published

    Cost of non-compliance and non-persistence with medications for diabetes mellitus

    Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Aug 2007.

    Research output: Contribution to conference › Paper

44. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conference › Paper

45. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conference › Paper

46. Published

    Cost-effectiveness considerations in pharmacogenetics.

    Hughes, D. & Hughes, D. A., 1 Jan 2008.

    Research output: Contribution to conference › Paper

47. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

48. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

49. Published

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 May 2008.

    Research output: Contribution to conference › Paper

50. Published

    Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Aug 2007.

    Research output: Contribution to conference › Paper

51. Published

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Dec 2003.

    Research output: Contribution to conference › Paper

52. Published

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

53. Published

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Jun 2008.

    Research output: Contribution to conference › Paper

54. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

55. Published

    Economic evaluation of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Jan 2009.

    Research output: Contribution to conference › Paper

56. Published

    Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Oct 2004.

    Research output: Contribution to conference › Paper

57. Published

    Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial

    Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Mar 2007.

    Research output: Contribution to conference › Paper

58. Published

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.

    Research output: Contribution to conference › Paper

59. Published

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.

    Research output: Contribution to conference › Paper

60. Published

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

61. Published

    Engaging with the MRC Methodology Hubs – NWHTMR.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

62. Published

    Enhancing methodical approaches for studying bilingualism in healthcare communication: report of a trial feasibility study.

    Roberts, G. W., Hughes, D., Roberts, G., Owen, H., Hughes, L., Whitaker, R., Deuchar, M., Hughes, D. A., Llewelyn, S., John, S., Irvine, F., Owen, B. & Rowlands, A., 1 Jan 2010.

    Research output: Contribution to conference › Paper

63. Published

    Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 May 2007.

    Research output: Contribution to conference › Paper

64. Published

    Falls and hip-fractures: A cost-effectiveness analysis of risk assessment and interventions for community-dwelling older people

    Hughes, D., Gwynne, D., Hughes, D. A. & Edwards, R. T., 1 Mar 2007.

    Research output: Contribution to conference › Paper

65. Published

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D. & Hughes, D. A., 1 May 2007.

    Research output: Contribution to conference › Paper

66. Published

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D., 1 Mar 2007.

    Research output: Contribution to conference › Paper

67. Published

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

68. Published

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 May 2002.

    Research output: Contribution to conference › Paper

69. Published

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Nov 2004.

    Research output: Contribution to conference › Paper

70. Published

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

71. Published

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Nov 2001.

    Research output: Contribution to conference › Paper

72. Published

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

73. Published

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Jan 2009.

    Research output: Contribution to conference › Paper

74. Published

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Sept 2007.

    Research output: Contribution to conference › Paper

75. Published

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conference › Paper

76. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

77. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

78. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009, p. O41.

    Research output: Contribution to conference › Paper

79. Published

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Nov 2005.

    Research output: Contribution to conference › Paper

80. Published

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Jan 2008.

    Research output: Contribution to conference › Paper

81. Published

    Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Oct 2007.

    Research output: Contribution to conference › Paper

82. Published

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

83. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

84. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.

    Research output: Contribution to conference › Paper

85. Published

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.

    Research output: Contribution to conference › Paper

86. Published

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Sept 2003.

    Research output: Contribution to conference › Paper

87. Published

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Nov 2007.

    Research output: Contribution to conference › Paper

88. Published

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 May 2004.

    Research output: Contribution to conference › Paper

89. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

90. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Oct 2001.

    Research output: Contribution to conference › Paper

91. Published

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.

    Research output: Contribution to conference › Paper

92. Published

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

93. Published

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Jul 2004.

    Research output: Contribution to conference › Paper

94. Published

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

95. Published

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Apr 2004.

    Research output: Contribution to conference › Paper

96. Published

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Jun 2005.

    Research output: Contribution to conference › Paper

97. Published

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.

    Research output: Contribution to conference › Paper

98. Published

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

99. Published

    Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

    Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Nov 2007.

    Research output: Contribution to conference › Paper

100. Published

     Pragmatic trials - design features and implications for clinical decision making

     Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Aug 2000.

     Research output: Contribution to conference › Paper

101. Published

     Prescription fee exemption research study

     Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Jun 2006.

     Research output: Contribution to conference › Paper

102. Published

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Jul 2005.

     Research output: Contribution to conference › Paper

103. Published

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Jan 2006.

     Research output: Contribution to conference › Paper

104. Published

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Nov 2005.

     Research output: Contribution to conference › Paper

105. Published

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Nov 2005.

     Research output: Contribution to conference › Paper

106. Published

     Public meetings of the NICE appraisals committee

     Hughes, D. & Hughes, D. A., 1 Dec 2007.

     Research output: Contribution to conference › Paper

107. Published

     Quantitative risk-benefit analysis

     Hughes, D. & Hughes, D. A., 1 May 2007.

     Research output: Contribution to conference › Paper

108. Published

     Rationing of drugs for rare diseases

     Hughes, D. & Hughes, D. A., 1 Apr 2006.

     Research output: Contribution to conference › Paper

109. Published

     Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

     Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Mar 2007.

     Research output: Contribution to conference › Paper

110. Published

     The all wales medicines strategy group: assessments and appraisals

     Hughes, D. & Hughes, D. A., 1 Nov 2008.

     Research output: Contribution to conference › Paper

111. Published

     The assessment, determinants & economics of medication compliance & persistence

     Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Oct 2007.

     Research output: Contribution to conference › Paper

112. Published

     The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

     Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.

     Research output: Contribution to conference › Paper

113. Published

     The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

     Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

     Research output: Contribution to conference › Paper

114. Published

     The economics of evergreening.

     Hughes, D. & Hughes, D. A., 1 Jan 2009.

     Research output: Contribution to conference › Paper

115. Published

     The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

     Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.

     Research output: Contribution to conference › Paper

116. Published

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

     Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.

     Research output: Contribution to conference › Paper

117. Published

     The pharmacokinetic profile of Warfarn: a systematic review

     Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Dec 2007.

     Research output: Contribution to conference › Paper

118. Published

     The population pharmacokinetics of lapdap

     Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.

     Research output: Contribution to conference › Paper

119. Published

     Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

     Hughes, D. & Hughes, D. A., 1 Nov 2006.

     Research output: Contribution to conference › Paper

120. Published

     Use of PK-PD modelling to predict the impact of non-compliance

     Hughes, D. & Hughes, D. A., 1 Nov 2003.

     Research output: Contribution to conference › Paper

121. Published

     What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

     Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 May 2007.

     Research output: Contribution to conference › Paper

122. Paper › Research › Peer-reviewed
123. Published

     A Systematic Review of Patient Preferences for Subcutaneous Medications

     Ridyard, C., Dawoud, D. & Hughes, D., Nov 2013.

     Research output: Contribution to conference › Paper › peer-review

124. Published

     Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

     Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Nov 2015.

     Research output: Contribution to conference › Paper › peer-review

125. Published

     Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation

     Ridyard, C. & Hughes, D., Nov 2013.

     Research output: Contribution to conference › Paper › peer-review

126. Published

     Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation

     Ridyard, C. & Hughes, D., Nov 2013.

     Research output: Contribution to conference › Paper › peer-review

127. Published

     Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

     Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Nov 2013.

     Research output: Contribution to conference › Paper › peer-review

128. Poster › Research › Peer-reviewed
129. Published

     Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

     Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Sept 2017.

     Research output: Contribution to conference › Poster › peer-review

130. Published

     Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials

     Culeddu, G., Hughes, D. & Welton, N., 10 Jul 2017.

     Research output: Contribution to conference › Poster › peer-review

131. Published

     Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

     Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 May 2017, p. P265. 1 p.

     Research output: Contribution to conference › Poster › peer-review

132. Published

     Health Economics Analysis Plans: Where Are We Now?

     Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Nov 2016, p. A397. 1 p.

     Research output: Contribution to conference › Poster › peer-review

133. Published

     Health economics analysis plans: the current state of play

     Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 May 2017, p. P144. 1 p.

     Research output: Contribution to conference › Poster › peer-review

134. Published

     Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations

     Ridyard, C. & Hughes, D., 7 May 2017, p. P141. 1 p.

     Research output: Contribution to conference › Poster › peer-review

135. Abstract › Research › Peer-reviewed
136. Published

     Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

     Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Sept 2017, p. 22-23.

     Research output: Contribution to conference › Abstract › peer-review

137. Other › Research › Peer-reviewed
138. Published

     Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

     Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

     Research output: Contribution to conference › Other › peer-review

139. Commissioned report › Research › Not peer-reviewed
140. Published

     A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

     Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

     Research output: Book/Report › Commissioned report

141. Published

     AWMSG criteria for appraising new medicines.

     Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

142. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

143. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

144. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

     Research output: Book/Report › Commissioned report

145. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

     Research output: Book/Report › Commissioned report

146. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

147. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

148. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

149. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

150. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

151. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

152. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

153. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

154. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

155. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

156. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

157. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

     Research output: Book/Report › Commissioned report

158. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

159. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

160. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

161. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

162. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

     Research output: Book/Report › Commissioned report

163. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

164. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

165. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

166. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

167. Published

     All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

168. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

169. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

170. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

171. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

172. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

173. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

174. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

175. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

176. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

177. Published

     All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

178. Published

     All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

179. Published

     Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

     Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

180. Published

     Follow-up of cancer patients in primary care versus secondary care: systematic review.

     Hughes, D., Lewis, R., Neal, R., Williams, N., France, B., Wilkinson, C., Hendry, M., Russell, D., Hughes, D. A., Russell, I. T., Stuart, N. S. & Weller, D., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

181. Published

     Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

     Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

     Research output: Book/Report › Commissioned report

182. Published

     Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

     Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

     Research output: Book/Report › Commissioned report

183. Published

     Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.

     Research output: Book/Report › Commissioned report

184. Published

     Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Jan 2006, 2006 ed. Unknown.

     Research output: Book/Report › Commissioned report

185. Published

     Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Feb 2006, Unknown.

     Research output: Book/Report › Commissioned report

186. Published

     Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2005, 2005 ed. Unknown.

     Research output: Book/Report › Commissioned report

187. Published

     Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

     Hughes, D. & Hughes, D. A., 1 Jan 2004, 2004 ed. Unknown.

     Research output: Book/Report › Commissioned report

188. Published

     Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

     Hughes, D. & Hughes, D. A., 1 Jan 2005, 2005 ed. Unknown.

     Research output: Book/Report › Commissioned report

189. Published

     Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

     Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

190. Published

     Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

     Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

     Research output: Book/Report › Commissioned report

191. Published

     Policy on ultra-orphan drugs.

     Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

192. Published

     Public health interventions to promote mental well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Windle, G., Hughes, D. A., Linck, P., Morgan, R., Burholt, V., Edwards, R. T., Reeves, C., Yeo, S. T., Woods, R. T. & Russell, I. T., 1 Jan 2007, 2007 ed. Unknown.

     Research output: Book/Report › Commissioned report

193. Published

     Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T., Morgan, R., Woods, R. T., Burholt, V., Edwards, R. T., Reeves, C. & Yeo, S. T., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

194. Published

     Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness: Evidence Tables.

     Hughes, D., Linck, P. G., Windle, G., Linck, P., Morgan, R., Hughes, D. A., Burholt, V., Reeves, C., Yeo, S. T., Woods, R. T., Edwards, R. T. & Russell, I. T., 1 Jan 2008, 2008 ed. Unknown.

     Research output: Book/Report › Commissioned report

195. Published

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

     Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

     Research output: Book/Report › Commissioned report

196. Published

     Welsh Health Economics Network (WHEN): Scoping Report.

     Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.

     Research output: Book/Report › Commissioned report

197. Published

     What is the effectiveness and cost-effectiveness of interventions in reducing the harms for children and young people who have been exposed to domestic violence or abuse: a rapid review.

     Spencer, L., Hendry, A., Makanjuola, A., Pisavadia, K., Davies, J., Albustami, M., Anthony, B., Wilkinson, C., Fitzsimmons, D., Hughes, D., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 10 May 2023, 79 p.

     Research output: Book/Report › Commissioned report

198. Commissioned report › Research › Peer-reviewed
199. Published

     What innovations can address inequalities experienced by women and girls due to the COVID-19 pandemic across the different areas of life/domains: work, health, living standards, personal security, participation and education? Report number – RR00027 (January 2022). Gender Inequalities: COVID-19 initiatives

     Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Pisavadia, K., Davies, J., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 15 Jan 2022, Health and Care Research Wales.

     Research output: Book/Report › Commissioned report › peer-review

200. Other report › Research › Not peer-reviewed
201. Published

     RES00019. Wales COVID-19 Evidence Centre. A rapid evidence summary indicating the evidence of the inverse care law in social care in Wales and has this been exacerbated by the COVID-19 pandemic?

     Spencer, L., Hendry, A., Makanjuola, A., Hughes, D., Wilkinson, C., Pisavadia, K., Davies, J., Fitzsimmons, D. & Edwards, R. T., Feb 2022, Welsh Government. 33 p.

     Research output: Book/Report › Other report

202. Published

     RES00038. Wales COVID-19 Evidence Centre. A rapid evidence summary of the cost impact of Long COVID on employment and caring responsibilities

     Spencer, L., Hendry, A., Davies, J., Pisavadia, K., Hughes, D. & Edwards, R. T., May 2022, Welsh Government. 18 p.

     Research output: Book/Report › Other report

203. Other report › Research › Peer-reviewed
204. Published

     Have infection control and prevention measures resulted in any adverse outcomes for care home and domiciliary care residents and staff? Report number: RR_00018 (November 2021)

     Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 1 Nov 2021, 36 p.

     Research output: Book/Report › Other report › peer-review

205. Web publication/site › Research
206. Published

     Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

     Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Mar 2008

     Research output: Non-textual form › Web publication/site

207. Review article › Research › Peer-reviewed
208. Published

     A Systematic Review of Economic Evaluations of Advanced Therapy Medicinal Products

     Lloyd Williams, H. & Hughes, D., Jun 2021, In: British Journal of Clinical Pharmacology. 87, 6, p. 2428-2443 16 p.

     Research output: Contribution to journal › Review article › peer-review

209. Published

     Evidence to support inclusion of pharmacogenetic biomarkers in randomised controlled trials

     Johnson, D., Jorgensen, A., Hughes, D. & Pirmohamed, M., 1 Sept 2019, In: Journal of Personalized Medicine. 9, 3, 19 p., 42.

     Research output: Contribution to journal › Review article › peer-review

210. Preprint › Research
211. Published

     The costs and cost-effectiveness of different service models of palliatice care, focusing on end of life care: A rapid review

     Spencer, L., Anthony, B., Davies, J., Pisavadia, K., Gillen, E., Noyes, J., Fitzsimmons, D., Lewis, R., Cooper, A., Hughes, D., Edwards, R. T. & Edwards, A., 7 Mar 2024, MedRxiv, 118 p.

     Research output: Working paper › Preprint

212. Published

     What interventions or best practice are there to support people with Long COVID, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review

     Spencer, L., Hendry, A., Makanjuola, A., Anthony, B., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 28 Jan 2023, 34 p. (MedRxiv).

     Research output: Working paper › Preprint

213. Published

     What is the long-term impact of COVID-19 on the Health-Related Quality of Life of individuals with mild symptoms (or non-hospitalised): A rapid review

     Spencer, L., Hendry, A., Makanjuola, A., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 9 Sept 2022, Health and Care Research Wales, 47 p.

     Research output: Working paper › Preprint